Found launched in 2019 with a different positioning than Calibrate or other GLP-1 weight loss platforms — a more flexible model with broader medication options, leaning toward a “right tool for your biology” framing rather than a one-size-fits-all GLP-1 push. Found is a telehealth weight-care service: board-certified clinicians (physicians or nurse practitioners) assess your eligibility, and any prescription is at their discretion. This found weight loss review covers 2026 pricing, the assessment-and-prescribing model, what is included, and how Found compares to Calibrate, Noom Med, Ro, and Hims weight loss programs. The headline: Found is more flexible than Calibrate but lighter on coaching, with a broader formulary that fits more patient profiles. This is an independent review, not medical or insurance advice, and it is not sponsored by Found.
How Found’s program works
Found’s intake includes a comprehensive metabolic health assessment covering hormonal factors, sleep, stress, behavioral patterns, prior weight loss history, and medical contraindications. A clinician reviews the assessment and selects from a broader formulary than most competitors — GLP-1 medications when appropriate, but also metformin, bupropion, naltrexone, topiramate, and Contrave (the bupropion-naltrexone combination), among others. Found is explicit that prescriptions remain “up to a medical provider’s discretion,” so this is prescriber-directed care: you describe your history and goals, and a licensed clinician decides what, if anything, is clinically appropriate. There is no self-selecting a drug.
Ongoing care includes clinician check-ins, asynchronous messaging with the prescriber, in-app tracking and behavioral coaching content, community support, and optional one-on-one coaching at higher tiers. The model is more medication-agnostic than Calibrate, recognizing that not every patient is a GLP-1 candidate and that for some patients, off-label use of older weight loss medications produces better outcomes at lower cost. For broader context, see our telehealth guide and best telehealth for weight loss roundup.
Found pricing in 2026
Pricing has been reshaped since Found’s early days, and the figures below were taken from Found’s own materials in 2026 — treat them as estimates and verify current pricing directly, because DTC weight-care pricing changes often. As of 2026, Found advertises non-GLP-1 medication plans starting around $49 per month, compounded GLP-1 options starting around $99 per month (with flat pricing as the dose increases), and brand-name GLP-1 plans “from about $650/month+” depending on the medication. Found also states that most members with insurance pay under $30 per clinical visit, and that prepaid annual plans lower the effective monthly cost.
Medication is generally separate from any program or visit fee. Generic medications like metformin, bupropion, and naltrexone often run $10-30 per month with insurance or through a pharmacy partner. Branded GLP-1s like Wegovy and Zepbound can exceed $1,000 per month at cash list price, though manufacturer savings programs and insurance coverage change what you actually pay when applicable. Found does not bill insurance as your medical plan and is not insurance; where GLP-1s are covered, Found coordinates prescriptions with pharmacies for insurance billing of the medication itself. The flexible monthly model is meaningfully different from Calibrate’s historical 12-month upfront commitment — patients can typically pause or cancel, which lowers the financial barrier to entry. See our healthcare costs guide for cost context against typical weight loss program pricing.
The Medicare GLP-1 Bridge
Found now advertises a “Medicare GLP-1 Bridge” aimed at adults roughly 65-75 who have Medicare Part D coverage, with a stated copay around $50 per month for eligible GLP-1s such as Wegovy, Zepbound, or Found’s newer oral option. Details, eligibility, and copays for any Medicare-linked offering depend on your specific Part D plan, formulary, and prior-authorization rules, and these programs change — confirm the current terms with Found and with your own plan before enrolling. Nothing here guarantees coverage or a particular price for your situation.
What Found prescribes that other platforms don’t
Found’s broad formulary is the primary clinical differentiator. Depending on the clinical assessment, the platform may prescribe:
- Metformin off-label for weight management in patients with insulin resistance markers
- Bupropion (Wellbutrin) off-label, particularly when weight is comorbid with depression
- Naltrexone, often combined with bupropion (Contrave is the FDA-approved combination)
- Topiramate off-label, often combined with phentermine (Qsymia is the FDA-approved combination)
- GLP-1 and dual-agonist medications including Wegovy, Zepbound, Ozempic, Mounjaro, and Saxenda/Victoza
- Compounded semaglutide and tirzepatide (availability narrowing — see below), plus newer oral GLP-1 options Found markets under its own branding
Found also lists newer options — including an oral GLP-1 it brands as “Foundayo” (orforglipron) and a lower-dose “microdosing” entry point. Availability and regulatory status for the newest products are evolving, so verify current details directly with Found rather than relying on any single source. Formulary breadth matters because not every patient responds best to GLP-1s, and not every patient can afford or access them. A patient with insulin resistance, mild obesity, and budget constraints may do well on metformin at a few dollars a month. A patient with comorbid depression may benefit from bupropion. This “match medication to patient” approach is closer to traditional bariatric medicine than to platforms that lead with GLP-1 marketing. Which medication is right — and at what dose — is a decision only your prescriber can make.
Compounded GLP-1s: what changed and the counterfeit risk
Compounded semaglutide and tirzepatide were widely offered during the national shortages of the brand-name drugs. That window has largely closed. After the U.S. Food and Drug Administration declared the tirzepatide and then the semaglutide shortages resolved, the enforcement grace periods that had allowed large-scale compounding of these GLP-1s ended in 2025. As a result, compounded GLP-1 availability is narrowing, and any patient who was on a compounded option may be transitioned to a brand-name product or an alternative. The FDA has repeatedly warned that counterfeit and illegally sold “semaglutide” or “tirzepatide” — especially products marketed online outside licensed U.S. pharmacies or as “research chemicals” — can contain the wrong drug, wrong dose, or contaminants. If you use any GLP-1, it should be dispensed through a licensed pharmacy under a prescription, never bought from an unverified seller. Customer-service complaints around medication delays, particularly for compounded options, were documented in 2024-2025 as this transition played out.
GLP-1 safety: the boxed warning and no self-dosing
GLP-1 medicines are powerful and are not appropriate for everyone. Per the FDA and MedlinePlus, semaglutide (and related GLP-1/dual-agonist drugs) carries a boxed warning for the risk of thyroid C-cell tumors, including medullary thyroid carcinoma, based on rodent studies; these drugs are contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Common side effects include nausea, vomiting, diarrhea, and constipation; serious risks include pancreatitis, gallbladder problems, kidney injury from dehydration, and allergic reactions. This article intentionally does not provide dosing or titration schedules — starting dose, escalation, and any changes are set individually by your prescriber. Report warning signs such as a neck lump, hoarseness, trouble swallowing, or severe abdominal pain to your clinician promptly.
The coaching component
Found’s coaching is lighter than Calibrate’s but real. Plans include app-based behavioral content covering nutrition, exercise, sleep, and emotional health, with check-ins through messaging and community support. Higher-tier plans add one-on-one coaching sessions, but the default experience is closer to “structured medication management with educational content” than Calibrate’s “intensive coaching with medication.”
For patients who want clinical medical management without intensive coaching, Found’s lighter approach is genuinely a feature. For patients who need accountability and structured behavior change support to succeed, a heavier coaching model may produce better outcomes. The honest comparison is that Found sits closer to traditional outpatient bariatric medicine while Calibrate sits closer to a structured weight loss program. Both are legitimate models with different value propositions. See our detailed Calibrate vs Found head-to-head for the full comparison.
Found’s clinical infrastructure
Found employs board-certified physicians and nurse practitioners with weight-management experience. The clinical assessment is thorough — the intake covers metabolic markers, hormonal factors, behavioral history, and contraindications in more depth than many DTC weight loss platforms — and clinicians use that data to inform medication selection rather than defaulting to a single drug.
Lab work is offered as an add-on. Patients can order metabolic labs (lipid panel, A1c, comprehensive metabolic panel, thyroid) through a lab partner and have results integrated into the clinical chart, which is more sophisticated than platforms that prescribe based purely on patient-reported information. The Obesity Medicine Association publishes professional standards for medical weight management; Found’s clinical model aligns more closely with these standards than many DTC competitors, though enrollment in any program is not a substitute for a relationship with your own physician.
Where Found falls short
The lighter coaching model means patients who need behavior-change support don’t get as much through Found as through Calibrate or Noom. For patients with strong self-direction and clear medical needs, this is a feature; for patients who’ve struggled with prior weight loss attempts due to lifestyle factors, the lighter coaching may not move outcomes enough.
Insurance integration is limited like most DTC platforms. Program and visit fees are largely out of pocket, and while Found helps coordinate GLP-1 insurance prescriptions, complex prior-authorization processes are still substantially patient-driven. Availability is also not universal — Found has stated it operates across most states but not all (it has cited coverage in 49 states, excluding California, for certain offerings). And, as noted, the wind-down of compounded GLP-1s has narrowed the low-cost injectable options that made Found attractive to price-sensitive patients.
Found vs Calibrate, Noom Med, Ro, and Hims
Compared to Calibrate, Found is more flexible and has broader medication options but lighter coaching. Compared to Noom Med, Found has stronger clinical infrastructure while Noom integrates a more comprehensive behavioral platform. See Found vs Noom for the head-to-head.
Compared to Ro and Hims weight loss, Found generally offers a more comprehensive clinical assessment and a broader medication menu. Ro and Hims primarily prescribe GLP-1 medications with a narrower alternative formulary; Found’s medication-agnostic approach fits a wider range of patient profiles. All of these platforms are telehealth prescribers, not insurers, and none is affiliated with FMHC.
Frequently Asked Questions
Does Found prescribe Wegovy and Zepbound?
Found lists FDA-approved GLP-1 medications including Wegovy, Zepbound, Ozempic, and Mounjaro among its options for eligible patients, alongside off-label and older weight-management drugs. Whether any of them is prescribed to you is a clinical decision made by a Found clinician based on your assessment.
Does Found take insurance?
Found is not insurance and generally does not bill insurance as your medical plan. It coordinates GLP-1 prescriptions through pharmacies where your insurance may cover the medication itself, and it says many members pay a reduced copay for clinical visits with insurance. Verify your plan’s GLP-1 coverage and any prior-authorization rules independently.
Is Found cheaper than Calibrate?
For the program/visit fee, often yes — Found’s monthly and per-visit pricing is typically lower than Calibrate’s historical multi-month commitment. Total cost depends heavily on which medication you take and your insurance coverage, which can be similar or very different across the two. Treat all figures as estimates and confirm current pricing.
Can I still get compounded semaglutide through Found?
Availability has narrowed. After the FDA declared the semaglutide and tirzepatide shortages resolved, the grace periods for compounding these drugs ended in 2025, so many patients are being moved to brand-name products or alternatives. Check Found’s current offerings directly, and never buy “GLP-1” from unverified online sellers.
What is the Medicare GLP-1 Bridge?
It is a Found offering aimed at adults roughly 65-75 with Medicare Part D, advertising a copay around $50/month for certain GLP-1s. Eligibility and cost depend entirely on your specific Part D plan and formulary, and these programs change — confirm current terms with Found and your plan.
Medical disclaimer: This article is an independent, general-information review and is not medical advice, insurance advice, or an endorsement. FMHC is not affiliated with Found and was not compensated for this review. Prices, programs, and drug availability change frequently; every dollar figure is an estimate you should verify directly with Found and your insurer. GLP-1 medications carry a boxed warning for thyroid tumors and are not appropriate for everyone — whether to use any medication, and at what dose, is a decision for you and a licensed clinician. Never buy prescription weight-loss drugs from unverified sellers.
The bottom line on Found
Found remains one of the more flexible medical weight-loss telehealth services, with a broad medication formulary and a subscription model that avoids a large upfront commitment. The clinical assessment is thorough and the medication-agnostic approach fits a wider range of patients than GLP-1-only platforms. The lighter coaching is a feature for self-directed patients and a weakness for those needing behavior-change support, and the wind-down of compounded GLP-1s has reshaped its low-cost options. For patients with insulin resistance, mild obesity, or budget constraints where GLP-1s aren’t the right first move, Found’s broader formulary can make it a stronger fit than GLP-1-first competitors — but the medication that’s right for you, if any, is a decision only your prescriber can make. Verify current pricing and program details with Found before enrolling.
Sources
- Found / joinfound.com — current programs, medications, and pricing (accessed 2026; subject to change, verify before relying)
- U.S. Food and Drug Administration — GLP-1 boxed warning; compounding of semaglutide/tirzepatide after shortage resolution; warnings about counterfeit and illegally marketed GLP-1 products
- MedlinePlus — semaglutide injection drug information (boxed warning, contraindications, side effects, prescription-only status)
- Obesity Medicine Association — professional standards for medical weight management